WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 ...

Initial Phase 1/2 data highlight the potential of Moderna's multiplexed mRNA approach in relapsed or refractory ...

Moderna surges on pre-earnings momentum, Pfizer dips after beating estimates and raising guidance, and Merck drops despite ...

Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.

Investors are thrilled with the results and the money that intismeran may bring in for Moderna in the future. CEO Stéphane ...

The stock has soared 650% this year, largely outperforming many tech giants, the stocks that have driven positive market ...

Moderna (MRNA) will advance its investigational mRNA-1469 vaccine candidate against Bundibugyo ebolavirus toward a phase 2/3 efficacy study in the Democratic Republic of the Congo ...

Moderna released full data on its closely watched cancer vaccine developed with Merck.

If it does turn again, the question is how much more the stock could lose on top of this drop: in past market-wide downturns, ...

Moderna’s stock has taken a big hit that might signal the end of this year’s cancer vaccine-driven rally. It may not, however ...

Moderna MRNA is scheduled to report third-quarter 2026 earnings on Nov. 6, before the opening bell. The Zacks Consensus ...

Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...